Werewolf Therapeutics (NASDAQ:HOWL) Announces Quarterly Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02, FiscalAI reports.

Werewolf Therapeutics Stock Performance

HOWL stock remained flat at $0.98 on Friday. The company had a trading volume of 317,208 shares, compared to its average volume of 2,348,430. The firm’s 50 day simple moving average is $0.98 and its two-hundred day simple moving average is $0.70. The company has a market cap of $47.63 million, a P/E ratio of -1.29 and a beta of 0.55. Werewolf Therapeutics has a one year low of $0.27 and a one year high of $1.20.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HOWL. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Finally, Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Get Our Latest Report on Werewolf Therapeutics

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.

Read More

Earnings History for Werewolf Therapeutics (NASDAQ:HOWL)

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.